Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Establishes Three New Centers of Excellence in Asia

Published: Tuesday, March 05, 2013
Last Updated: Monday, March 04, 2013
Bookmark and Share
Centers will apply Horizon’s rAAV gene editing technology to a range of oncology research projects.

Horizon Discovery has announced that it has established three new Centers of Excellence (CoE’s) for gene editing in Asia.

The new Centers are at Aichi Cancer Center, Japan, Seoul National University, South Korea, and the National Cancer Centre (NCC), Singapore.

Horizon will support the three research centers in their application of its proprietary gene engineering technology, GENESIS™, to generate human isogenic cell lines harboring specific genes/mutations relating to cancer.

The Aichi Cancer Center is Horizon’s third CoE in Japan, and will focus on elucidation of the molecular mechanisms of viral proliferation and oncogenesis of Epstein Barr Virus, as part of the world-wide effort to combat virally-initiated cancers. The PI for this program will be Takayuki Murata.

Seoul National University, Institute of Molecular Biology and Genetics, will work with Horizon to create isogenic cell lines to study the regulatory mechanisms of BubR1 spindle assembly checkpoint, in order to increase understanding of the basis of genetic instability of cancer.

Associate Professor Hyunsook Lee will be leading the program for Seoul National University.

Dr Daniel SW Tan, PI at the NCC Singapore, Department of Medical Oncology, will use Horizon’s technology to study the effects on cell lines of cancer-causing EGFR mutations, which are implicated in a wide range of cancer types.

“We are delighted these three new institutes have joined our Centers of Excellence program,” said Dr Rob Howes, Principal Scientist, Horizon. “We are excited to continue expanding our rAAV genome editing network into Asia, and hope to add to this further through 2013.”

The new human isogenic cell lines generated by the CoE’s will be exclusively licensed to Horizon in return for future product royalties.

Horizon will also have an exclusive option to license new intellectual property developed. This forms part of Horizon’s strategy to generate at least 2500 new X-MAN™ (gene X- Mutant And Normal) models of cancer, neurodegenerative, and cardiovascular disease.

These models support drug discovery researchers in their efforts to understand how complex genetic diseases manifest themselves in real patients, and help rationalize many aspects of drug development, reducing the cost of bringing to market new personalized therapies.

These centers become part of the larger Horizon Centers of Excellence network, which includes high profile Institutions such as Cambridge University, UCL, Yale University, the National Cancer Institute, Washington University in St Louis and the National Cancer Centre, Japan.

Horizon sponsors an online community portal, www.rAAVers.org, for scientists working with rAAV-mediated and other forms of genome editing.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
Horizon to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Friday, March 13, 2015
Horizon Discovery Appoints Dr David Smoller as an Executive Director
Company announces the appointment of Dr David Smoller, Chief Business Officer of Horizon, as an Executive Director of the Board, with immediate effect.
Monday, November 03, 2014
Horizon Signs Master Services Agreement for Approximately $1.2 Million
Agreement covers development of molecular reference standards for companion diagnostics.
Friday, September 26, 2014
Horizon Discovery Adds Three Eminent CRISPR Experts to its SAB
Dr. Emmanuelle Charpentier, Dr. J. Keith Joung, and Dr. Feng Zhang join the Company’s panel of expert gene editing advisors.
Tuesday, August 05, 2014
Horizon and OPDC Sign Collaboration Agreement
Horizon CombinatoRx to perform in-vitro cell line screening of OPDC clinical stage development candidates.
Friday, July 25, 2014
Horizon Licenses AAV Gene Delivery Technology from Stanford University
Agreement supplements existing exclusive rAAV gene targeting license from University of Washington.
Thursday, July 03, 2014
Horizon, LGC Awarded Technology Strategy Board Grant
Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies.
Tuesday, June 17, 2014
Horizon Discovery Licenses CRISPR Gene Editing Technology
The Company announced it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system.
Thursday, June 12, 2014
Horizon Completes Acquisition of CombinatoRx from Zalicus
Acquisition of revenue generating and complementary business establishes Horizon’s headquarters in North America.
Monday, June 02, 2014
Horizon to Acquire CombinatoRx Service Business and Assets from Zalicus
Horizon Discovery Group has agreed to acquire the CombinatoRx service business and related assets from Zalicus Inc for £4.7M.
Thursday, May 15, 2014
Horizon Licenses CRISPR/Cas9 Gene Editing Technology from ERS Genomics
Horizon has entered into a non-exclusive license agreement with ERS.
Saturday, May 10, 2014
Horizon, Sirion Sign Supply and Distribution Agreement
Agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering.
Monday, February 17, 2014
Horizon Discovery and Transgenomic Collaborate
Collaboration agreement aims to develop improved genetic diagnostic tests incorporating state of the art controls.
Thursday, January 16, 2014
Horizon, AstraZeneca Announce Oncology Agreement
Research, collaboration and license agreement to explore a range of oncology-relevant genotypes.
Tuesday, January 07, 2014
Scientific News
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Imaging Software Could Speed Up Breast Cancer Diagnosis
Researchers use high speed optical microscopy of intact breast tissue specimens to analyze breast tissue.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Synthetic DNA Vaccine Against MERS Shows Promise
A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species.
How Small RNA Helps Form Memories
In a new study, a team of scientists at Scripps Florida has found that a type of genetic material called "microRNA" (miRNA) plays surprisingly different roles in the formation of memory in animal models.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!